BRISTOL MYERS SQUIBB CO (BMY) Form 8-K — Jul 30, 2026

$BMYForm 8-KItems 2.02, 7.01, 9.01Filed Jul 30, 2026, 7:05 AM ET0000014272-26-000018Original filing

Bristol-Myers Squibb reported second-quarter 2026 revenue of $13.0 billion, up 6% year-over-year, driven by a 15% increase in its Growth Portfolio to $7.6 billion. The company raised its full-year 2026 revenue guidance to approximately $49.0 billion to $50.0 billion and increased its non-GAAP EPS outlook to $6.75 to $7.00. Strong performance was led by double-digit growth in newer products like Breyanzi, Camzyos, and Reblozyl, which helped offset declines in legacy brands such as Revlimid and Pomalyst. Non-GAAP EPS for the quarter was $2.04, up 40% from the prior year, reflecting improved operational execution and a favorable product mix.

Key figures

Eps: $2.04
Revenue: $12.973 billion
Net Income: $3.317 billion
Total Debt: $43.12 billion
Revenue Yoy: 6%
Cash Position: $11.464 billion
Net Debt: -$31.656 billion
GAAP EPS: $1.62
Non GAAPEPS: $2.04
Guidance EPS2026: $6.75 - $7.00
Guidance Revenue2026: $49.0 billion - $50.0 billion
Growth Portfolio Growth: 15%
Growth Portfolio Revenue: $7.6 billion

Price after filing

1 day: -0.8%7 days: +0.9%30 days: +4.7%

Close on the filing date to close N calendar days later (from $63.60). Historical, not a forecast.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.